US 10858335
2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use
granted A61KA61K2039/505A61K31/4439
Quick answer
US patent 10858335 (2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use) held by Rigel Pharmaceuticals, Inc. expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61K, A61K2039/505, A61K31/4439, A61K31/444, A61K31/517